Literature DB >> 7702142

Adrenaline administered via a nebulizer in adult patients with upper airway obstruction.

S P MacDonnell1, A C Timmins, J D Watson.   

Abstract

Racemic adrenaline administered via a nebulizer has been used successfully in children with upper airway obstruction resulting from croup and postintubation oedema. We report four adult cases of upper airway obstruction of differing aetiologies successfully managed with the administration of adrenaline via a nebulizer (1 mg in 5 ml of normal saline and repeated as necessary). This appears to be safe and effective in selected cases of upper airway obstruction with immediate benefits and few cardiovascular sequelae.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702142     DOI: 10.1111/j.1365-2044.1995.tb04510.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  5 in total

1.  A descriptive survey of tracheal extubation practices among Indian anaesthesiologists.

Authors:  Sakshi Thakore; Pankaj Kundra; Rakesh Garg
Journal:  Indian J Anaesth       Date:  2021-03-13

Review 2.  [Difficult extubation].

Authors:  W Windisch; C Karagiannidis
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-08-26       Impact factor: 0.840

Review 3.  Postextubation laryngeal edema and stridor resulting in respiratory failure in critically ill adult patients: updated review.

Authors:  Wouter A Pluijms; Walther Nka van Mook; Bastiaan Hj Wittekamp; Dennis Cjj Bergmans
Journal:  Crit Care       Date:  2015-09-23       Impact factor: 9.097

4.  Treatment of upper airway oedema prior to extubation.

Authors:  Suruchi Ambasta; Priya Rudingwa; Pankaj Kundra; Rajiev Gnanasekar
Journal:  Indian J Anaesth       Date:  2016-10

Review 5.  Clinical review: post-extubation laryngeal edema and extubation failure in critically ill adult patients.

Authors:  Bastiaan H J Wittekamp; Walther N K A van Mook; Dave H T Tjan; Jan Harm Zwaveling; Dennis C J J Bergmans
Journal:  Crit Care       Date:  2009-12-01       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.